These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27000800)

  • 41. An analysis of legal warnings after drug approval in Thailand.
    Sriphiromya P; Theeraroungchaisri A
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):108-13. PubMed ID: 25445000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
    Am J Health Syst Pharm; 2016 Jun; 73(11):739-40. PubMed ID: 27208054
    [No Abstract]   [Full Text] [Related]  

  • 44. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
    Willy ME; Li Z
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 47. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, April-June 2018.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Sep; 75(17):e642-e653. PubMed ID: 30139737
    [No Abstract]   [Full Text] [Related]  

  • 48. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
    Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
    [No Abstract]   [Full Text] [Related]  

  • 49. The FDA, contraceptive marketing approval and products liability litigation: Depo-Provera and the risk of osteoporosis.
    Green W
    Food Drug Law J; 2013; 68(2):115-35, i. PubMed ID: 24640465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
    Shimazawa R; Ikeda M
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
    Greene MF
    Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
    Song YK; Han N; Burckart GJ; Oh JM
    Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The need for contraception in patients taking prescription drugs: a review of FDA warning labels, duration of effects, and mechanisms of action.
    Zhang Z; Xu L; Zhang Z; Ding H; Rayburn ER; Li H
    Expert Opin Drug Saf; 2018 Dec; 17(12):1171-1183. PubMed ID: 30394114
    [No Abstract]   [Full Text] [Related]  

  • 54. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rose B
    Hosp Pharm; 2016 Jun; 51(6):491-2. PubMed ID: 27354752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights October - December 2016.
    Rose BJ
    Hosp Pharm; 2017 Feb; 52(2):153-154. PubMed ID: 28321144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights July-September 2016.
    Rubio T
    Hosp Pharm; 2016 Dec; 51(11):941-943. PubMed ID: 28057955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
    Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL
    J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.